Children's Mercy Kansas City

SHARE @ Children's Mercy

Manuscripts, Articles, Book Chapters and Other Papers

11-30-2016

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

George S. Laszlo

Todd A. Alonzo

Chelsea J. Gudgeon

Kimberly H. Harrington

Alex Kentsis

See next page for additional authors

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Part of the Hemic and Lymphatic Diseases Commons, Medical Genetics Commons, Neoplasms Commons, Oncology Commons, and the Pediatrics Commons

Recommended Citation

Laszlo GS, Alonzo TA, Gudgeon CJ, et al. Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2016;9(1):133. Published 2016 Nov 30. doi:10.1186/s13045-016-0364-0

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Creator(s) George S. Laszlo, Todd A. Alonzo, Chelsea J. Gudgeon, Kimberly H. Harrington, Alex Kentsis, Robert B. Gerbing, Yi-Cheng Wang, Rhonda E. Ries, Susana C. Raimondi, Betsy A. Hirsch, A S. Gamis, Soheil Meshinchi, and Roland B. Walter

ERRATUM Open Access



Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group

George S. Laszlo¹, Todd A. Alonzo^{2,3}, Chelsea J. Gudgeon¹, Kimberly H. Harrington¹, Alex Kentsis^{4,5,6}, Robert B. Gerbing³, Yi-Cheng Wang³, Rhonda E. Ries¹, Susana C. Raimondi^{3,7}, Betsy A. Hirsch^{3,8}, Alan S. Gamis^{3,9}, Soheil Meshinchi^{1,3,10} and Roland B. Walter^{1,11,12*}

Erratum

The original article [1] contains an omission of information in the **Financial support** sub-section of the **Declarations** section.

The authors would like to acknowledge the Andrew McDonough B+ Foundation for financial support of coauthor Dr Yi-Cheng Wang throughout this study, and regret this inadvertent omission from the original publication.

Author details

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA. ²Department of Biostatistics, University of Southern California, Los Angeles, CA, USA. ³Children's Oncology Group, Monrovia, CA, USA. ⁴Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA. ⁵Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ⁵Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. ⁸Department of Laboratory Medicine and Pathology, University of Minnesota Cancer Center, Minneapolis, MN, USA. ⁹Division of Hematology-Oncology, Children's Mercy Hospitals and Clinics, Kansas City, MO, USA. ¹⁰Department of Pediatrics, University of Washington, Seattle, WA, USA. ¹¹Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA. ¹²Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹³Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁴Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁵Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁶Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁷Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁸Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁸Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology, University of Washington, Seattle, WA, USA. ¹⁹Department of Epidemiology

Received: 17 November 2016 Accepted: 28 November 2016 Published online: 30 November 2016

Full list of author information is available at the end of the article

Reference

 Laszlo GS, et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Hematol Oncol. 2015;8:115. doi:10.1186/s13045-015-0215-4.



^{*} Correspondence: rwalter@fredhutch.org

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2-190, Seattle, WA 98109-1024, USA

¹¹Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA